Literature DB >> 16463352

Botulinum toxin changes intrafusal feedback in dystonia: a study with the tonic vibration reflex.

Carlo Trompetto1, Antonio Currà, Alessandro Buccolieri, Antonello Suppa, Giovanni Abbruzzese, Alfredo Berardelli.   

Abstract

To investigate the possible role of botulinum toxin (BT-A) injection in reducing muscle afferent feedback, we evaluated electrophysiologically 10 right-handed patients with writer's cramp before and 3 weeks after treatment. The ratio between pre- and postinjection values of maximal M-wave (M-max), maximal voluntary contraction (MVC), and tonic vibration reflex (TVR) were measured in the injected muscles (wrist flexors or extensors). In all the subjects, BT-A injection reduced the TVR more than the M-max and MVC (mean ratio +/- SD: TVR, 0.24 +/- 0.22; MVC, 0.59 +/- 0.32; M-max, 0.68 +/- 0.24; P = 0.003). Long-term evaluation of 2 patients disclosed that, after 7 months, when some clinical benefits persisted, M-max and MVC had fully recovered, whereas the TVR was still depressed. This special sensitivity of the TVR to suppression by BT-A injection could be mediated by the chemodenervation of intrafusal muscle fibers, leading to a reduction in spindle inflow to the central nervous system during vibration. The action on intrafusal fibers could alter sensorimotor integration, thus contributing to the clinical benefits of BT-A injection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16463352     DOI: 10.1002/mds.20801

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  25 in total

Review 1.  Neurophysiological effects of botulinum toxin type A.

Authors:  G Abbruzzese; A Berardelli
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

2.  Negative dystonia of the palate: a novel entity and diagnostic consideration in hypernasal speech.

Authors:  Catherine F Sinclair; Kristina Simonyan; Mitchell F Brin; Andrew Blitzer
Journal:  Laryngoscope       Date:  2015-02-03       Impact factor: 3.325

3.  The effect of a single botulinum toxin treatment on somatosensory processing in idiopathic isolated cervical dystonia: an observational study.

Authors:  Joke De Pauw; Patrick Cras; Steven Truijen; Rudy Mercelis; Sarah Michiels; Wim Saeys; Luc Vereeck; Ann Hallemans; Willem De Hertogh
Journal:  J Neurol       Date:  2018-09-08       Impact factor: 4.849

Review 4.  Mechanism of action of botulinum neurotoxin: Unexpected consequences.

Authors:  Mark Hallett
Journal:  Toxicon       Date:  2017-08-11       Impact factor: 3.033

Review 5.  Sensory aspects of movement disorders.

Authors:  Neepa Patel; Joseph Jankovic; Mark Hallett
Journal:  Lancet Neurol       Date:  2014-01       Impact factor: 44.182

6.  Transynaptic Action of Botulinum Neurotoxin Type A at Central Cholinergic Boutons.

Authors:  Matteo Caleo; Matteo Spinelli; Francesca Colosimo; Ivica Matak; Ornella Rossetto; Zdravko Lackovic; Laura Restani
Journal:  J Neurosci       Date:  2018-10-12       Impact factor: 6.167

7.  Abnormal functional connectivity in focal hand dystonia: mutual information analysis in EEG.

Authors:  Seung-Hyun Jin; Peter Lin; Sungyoung Auh; Mark Hallett
Journal:  Mov Disord       Date:  2011-04-19       Impact factor: 10.338

Review 8.  Treatment and physiology in Parkinson's disease and dystonia: using transcranial magnetic stimulation to uncover the mechanisms of action.

Authors:  Aparna Wagle Shukla; David E Vaillancourt
Journal:  Curr Neurol Neurosci Rep       Date:  2014-06       Impact factor: 5.081

9.  Sporadic adult onset dystonia: sensory abnormalities as an endophenotype in unaffected relatives.

Authors:  Richard Walsh; John P O'Dwyer; Ifthikar H Sheikh; Sean O'Riordan; Tim Lynch; Michael Hutchinson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-09       Impact factor: 10.154

10.  Botulinum neurotoxin treatment improves force regulation in writer's cramp.

Authors:  Kirsten E Zeuner; Arne Knutzen; Lucas Pedack; Mark Hallett; Günther Deuschl; Jens Volkmann
Journal:  Parkinsonism Relat Disord       Date:  2013-03-16       Impact factor: 4.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.